Price
No data yet.
Social Signal Score
Analyst Ratings
7 analystsRevenue
$9.83MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Arun Swarup Menawat
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 162
- Beta
- 0.53
- Country
- CA
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 4.79
Financials
Revenue
$9.83M+1561.8%Net Income
$-7.72MEBITDA
$-7.73MFree Cash Flow
$-5.01MEPS (diluted)
$-0.21Shares Outstanding (diluted)
36.56M+560.9%Operating Expenses
$15.50MCash & Debt
$33.34MRevenue by Segment (annual)
$16.10MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $16.38M | $-43.32M | $-1.43 |
| 2024 | $10.17M | $-26.48M | $-1.07 |
| 2023 | $7.20M | $-28.57M | $-1.35 |
| 2022 | $6.68M | $-28.67M | $-1.38 |
| 2021 | $6.87M | $-30.70M | $-1.50 |
| 2020 | $7.30M | $-21.62M | $-1.25 |
| 2019 | $4.17M | $-15.22M | $-1.39 |
| 2018 | $1.91M | $-15.24M | $-1.52 |
| 2017 | $4.90M | $-19.10M | $-2.44 |
| 2016 | $0.00 | $-12.15M | $-3.93 |
| 2015 | $0.00 | $-11.80M | $-6.91 |
| 2014 | $0.00 | $-8.20M | $-37.86 |
| 2013 | $0.00 | $-14.22M | $-65.62 |
| 2012 | $0.00 | $-9.14M | $-42.17 |
Valuation
PROFhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-28.57%Social Signal Score
Mentions (11)
- Newsglobenewswire.com·13d ago·Neutral
Profound Medical to Participate in the Stifel 2026 Healthcare Conference TORONTO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, today announced that its President, Richard Fabian, will present at the Stifel 2026 Healthcare Conference on Thursday, November 12, 2026 at 8:40 a.m. Eastern Time in NYC.
View source ↗ - Newsmarketbeat.com·16d ago·Neutral
What Profound Medical (PROF) Said on Its Q3 Earnings Call Profound Medical NASDAQ: PROF reported an 86% increase in third-quarter revenue and raised its full-year revenue outlook, as sales of its TULSA-PRO equipment helped drive growth ahead of a planned leadership transition.
View source ↗ - Newszacks.com·17d ago·Neutral
Profound Medical (PROF) Expected to Beat Earnings Estimates: Should You Buy? Profound Medical (PROF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
View source ↗ - Newszacks.com·23d ago·Positive
Wall Street Analysts Believe Profound Medical (PROF) Could Rally 89.93%: Here's is How to Trade The average of price targets set by Wall Street analysts indicates a potential upside of 89.9% in Profound Medical (PROF). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
View source ↗ - Newsglobenewswire.com·23d ago·Neutral
Profound Medical and Cook Medical's iMRI Division Partner to Expand U.S. TULSA-PRO® Sales Channels and Drive Recurring Revenue Growth New distribution agreement positions TULSA-PRO within the iMRI Suite offering through Cook Medical's Copernicus™ program, expanding Profound's commercial reach
View source ↗ - Newsglobenewswire.com·31d ago·Positive
Emmy-Award Winning Television Host Montel Williams to Join Next ‘Let's Huddle' Webinar TORONTO, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) today announced that Emmy Award-winning television host, health advocate and decorated U.S. Navy veteran, Montel Williams, will join the next Let's Huddle webinar for a discussion with its host, Leonard Wheeler, on November 5, 2026, at 3:00 p.m. ET. Mr. Williams will share his personal perspe…
View source ↗ - Newsglobenewswire.com·39d ago·Neutral
…trengthen Real-World Evidence, Clinical Differentiation, and Platform Expansion Opportunity TORONTO, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) today announced that five abstracts presented at the 15th Interventional MRI (“iMRI”) Symposium in Boston, Massachusetts, reinforce the growing body of evidence supporting the real-world performance, clinical differentiation, and platform expansion potential of the TULSA Procedure™ perfor…
View source ↗ - Newszacks.com·44d ago·Neutral
Strength Seen in Profound Medical (PROF): Can Its 21.7% Jump Turn into More Strength? Profound Medical (PROF) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
View source ↗ - Newsglobenewswire.com·46d ago·Positive
Profound Medical Reports Strong Preliminary Third Quarter 2026 Revenue Anticipates Q3-2026 revenue of $9.8 million to $10.0 million, exceeding Bloomberg analyst consensus by approximately 45% to 47% Anticipates Q3-2026 revenue of $9.8 million to $10.0 million, exceeding Bloomberg analyst consensus by approximately 45% to 47%
View source ↗ - Newsglobenewswire.com·80d ago·Positive
Profound Medical to Participate in Lake Street's 10th Annual Best Ideas Growth Conference TORONTO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, announced today that management will participate in the Lake Street Capital Markets “BIG10” Conference on September 10, 2026 in New York City.
View source ↗ - Newsglobenewswire.com·100d ago·Neutral
Profound Medical Announces Management Change TORONTO, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, today announced the promotion of Matthew Sobczyk from Corporate Controller to Interim Chief Financial Officer, effective immediately. Mr. Sobczyk, who first joined Profound in 2020, succeeds Rashed Dewan, who has stepp…
View source ↗
Earnings
Thu, Mar 4(in 3 months)
Consensus estimate $-0.26 per share
Typical surprise -10.5% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$-0.21 vs $-0.19miss
- Thu, Aug 6$-0.26 vs $-0.22miss
- Thu, May 7$-0.19 vs $-0.24beat
- Thu, Mar 5$-0.27 vs $-0.27beat
- Thu, Nov 13$-0.26 vs $-0.38beat
- Thu, Aug 14$-0.52 vs $-0.43miss
Estimates and results for PROF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by PROF officers and directors.
- Bought
- $100k
- Sold
- —
2 trades
0 trades
- Menawat Arun Swarupbought
- Menawat Arun Swarupbought
Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Tom Malinowskihouse · NJ07 · disclosed Mar 5, 2021 (441d later)Buy$1,001 - $15,000
- Tom Malinowskihouse · NJ07 · disclosed Mar 5, 2021 (227d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
